Zeina Nahleh, MD, Cancer Center Director and Regional Chair of Hematology Oncology at Cleveland Clinic in Florida joins the Cancer Advances Podcast to discuss the latest breakthroughs in treating brain metastasis in breast cancer patients. Listen as Dr. Nahleh shares insights into the challenges of managing this complex condition, highlights key findings from her recent study, and emphasizes the critical role of combining local and systemic therapies. Discover what the future holds with emerging treatments and how they may improve patient outcomes in this evolving field.

Gregory Videtic, MD, Director of the Thoracic Radiation Oncology Program at Cleveland Clinic, joins the 200th episode of the Cancer Advances podcast to talk about neuroprotection in patients with small cell lung cancer. Listen as Dr. Videtic explains the findings of the NRG CC003 trial, which examined how hippocampal-sparing radiation could minimize memory-related side effects while maintaining cancer control.

The Cancer Advances podcast is joined by Ofer Reizes, PhD, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research, and Roberto Vargas, MD, Gynecologic Oncologist and Program Director for the Gynecologic Oncology Fellowship to discuss their research on targeting CD55 to combat chemoresistance in ovarian cancer patients. Listen as they insights into the mechanisms behind chemoresistance, the challenges it presents in treatment, and the potential for innovative therapies to transform patient outcomes.

Arun D. Singh, MD, Director of Ophthalmic Oncology at Cleveland Clinic Cole Eye Institute, returns to the Cancer Advances podcast to discuss iris melanoma. Listen as Dr. Singh talks about the unique characteristics of this rare eye cancer, the latest advancements in diagnosis and treatment, including cutting-edge imaging techniques and the potential of machine learning. Tune in for this insightful discussion on this rare type of melanoma.

The Cancer Advances podcast is joined by third-year internal medicine resident, Heya Batah, MD, and hematologist and medical oncologist, Moaath Khader Mustafa Ali, MD, MPH to discuss the latest findings on the combination of atezolizumab with carboplatin and etoposide in treating extensive stage small cell lung cancer. Listen as they talk about the real-world data presented by Dr. Batah at ASCO, focusing on the impact of atezolizumab on overall survival and progression-free survival compared to traditional chemotherapy alone.

Shlomo Koyfman, MD, Director of Head and Neck and Skin Radiation at Cleveland Clinic, joins the Cancer Advances podcast to talk about the latest ASCO clinical practice guidelines for managing osteoradionecrosis, a potential complication due to radiation therapy. Listen as Dr. Koyfman discuss how the new guidelines are designed to enhance the prevention, early detection, and management of osteoradionecrosis. He shares insights into how these guidelines can be put into practice, and the impact of these new strategies on patient care and survivorship.

Thach-Giao Truong, MD, Director of the Melanoma Program at Cleveland Clinic, joins the Cancer Advances podcast to discuss Tumor-Infiltrating Lymphocyte (TIL) therapy. This cutting-edge, personalized cancer treatment utilizes a patient's immune cells to target and destroy tumors. Listen as Dr. Truong provides insights into the science behind TIL therapy, its advantages, and its potential to revolutionize treatment for patients with resistant melanoma and other challenging cancers.

Lily Wang, PhD, from the Department of Translational Hematology Oncology Research at Cleveland Clinic, joins the Cancer Advances Podcast to dive into her research on VISTA and LRIG1 interactions. Dr. Wang, an expert in immune mechanisms within cancer, discusses her lab's innovative work on these immune checkpoint proteins and their potential to overcome current treatment limitations. Discover how targeting the VISTA-LRIG1 axis could offer new strategies for tackling resistant tumors and improving patient outcomes.